Parkinson's drug repurposed to fight kidney disease?

NCT ID NCT06291116

Recruiting now Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a rotigotine skin patch, a drug used for Parkinson's disease, is safe for people with autosomal dominant polycystic kidney disease (ADPKD). ADPKD causes fluid-filled cysts in the kidneys and can lead to kidney failure. The trial will give 120 adults either standard care plus the rotigotine patch or standard care alone for 24 months, monitoring side effects and early signs of kidney protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rotigotine (a dopamine agonist given as a skin patch)
What this could lead to: If it works, this could point toward a new way to slow kidney function loss and heart problems in people with ADPKD.
What could go wrong: This is an early Phase 2 safety study with only 120 people. It may not show clear benefit, and side effects like skin reactions or behavior changes are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant polycystic kidney disease kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY DISEASES

Contacts and locations

Locations

CHRU de CAEN
RECRUITING

Caen, 14033, France
CHU d'AMIENS
RECRUITING

Amiens, 80054, France
CHU de LILLE
RECRUITING

Lille, 59037, France
CHU de ROUEN
RECRUITING

Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.